Lung Cancer - Multimodality Therapy

JANS Article

Surgical Outcomes After Chemotherapy Plus Nivolumab and Chemotherapy Plus Nivolumab and Ipilimumab in Patients With Non-Small Cell Lung Cancer

April 18, 2024 | Mujtaba MubashirGold Contributor

This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two patients were treated with nivolumab...

JANS Article

Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid

September 10, 2026 | Akshay PatelSilver Contributor

In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...

JANS Article

Surgical Outcomes After Chemotherapy Plus Nivolumab and Chemotherapy Plus Nivolumab and Ipilimumab in Patients With Non-Small Cell Lung Cancer

April 18, 2024 | Mujtaba MubashirGold Contributor

This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer

November 9, 2023 | Javeria Tariq

This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received...

JANS Article

Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

February 5, 2018 | Mark FergusonBronze Contributor

This randomized trial compared chemoradiotherapy alone to chemoradiotherapy followed by consolidation therapy with the PDL-1 antibody durvalumab in patients with stage III NSCLC. The treatment group had significantly improved progression-free...

JANS Article

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

October 24, 2017 | Mark FergusonBronze Contributor

A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.

...
JANS Article

Scientific Advances in Thoracic Oncology 2016

August 2, 2017 | Mark FergusonBronze Contributor

This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by...

JANS Article

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer

August 28, 2016 | Mark FergusonBronze Contributor

The authors tested the hypothesis that induction therapy improves survival in patients undergoing resection for clinical N1 disease using information from the National Cancer Data Base. 10% of over 5,000...

JANS Article

Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe

July 15, 2016 | Lisa Brown

This is a retrospective National Cancer Data Base cohort study of patients with pathologic stage T3 invasive NSCLC with separate tumor nodules in the same lobe. The goal was to...

JANS Article

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

November 16, 2015 | Mark FergusonBronze Contributor

The relationship to institution type and survival after multimodality therapy for IIIA NSCLC was investigated using the NCDB (National Cancer Database). Academic medical centers had a higher incidence of induction...

JANS Article

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

September 12, 2015 | Mark FergusonBronze Contributor

This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts...

JANS Article

Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials

July 14, 2015 | Mark FergusonBronze Contributor

This meta-analysis evaluated results from 6 studies totalling 868 patients randomized to local control (radiotherapy vs surgery) after induction therapy for NSCLC with N2 disease. Four studies evaluated induction chemotherapy,...

LOAD MORE
ADVERTISE ON CTSNET